CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Sage Therapeutics, Inc. - SAGE CFD

    19.60
    1.65%
    0.16
    Low: 19.38
    High: 20.07
    Market Trading Hours* (UTC) Open now
    Closes on Thursday at 21:00

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.16
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    SAGE Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 19.41
    Open* 19.38
    1-Year Change* -49.56%
    Day's Range* 19.38 - 20.07
    52 wk Range 16.52-59.99
    Average Volume (10 days) 945.50K
    Average Volume (3 months) 23.51M
    Market Cap 1.16B
    P/E Ratio -100.00K
    Shares Outstanding 59.97M
    Revenue 11.35M
    EPS -10.98
    Dividend (Yield %) N/A
    Beta 1.11
    Next Earnings Date Feb 14, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 29, 2023 19.41 0.31 1.62% 19.10 19.89 19.10
    Nov 28, 2023 19.21 0.63 3.39% 18.58 19.27 18.31
    Nov 27, 2023 18.98 -0.23 -1.20% 19.21 19.21 18.60
    Nov 24, 2023 19.44 0.11 0.57% 19.33 19.82 19.26
    Nov 22, 2023 19.36 0.02 0.10% 19.34 19.68 19.00
    Nov 21, 2023 19.26 0.02 0.10% 19.24 19.68 19.10
    Nov 20, 2023 19.65 0.69 3.64% 18.96 19.68 18.70
    Nov 17, 2023 19.10 0.46 2.47% 18.64 19.36 18.45
    Nov 16, 2023 18.53 -0.25 -1.33% 18.78 18.79 18.08
    Nov 15, 2023 19.15 0.11 0.58% 19.04 19.82 19.04
    Nov 14, 2023 19.24 1.16 6.42% 18.08 19.25 18.08
    Nov 13, 2023 17.25 0.49 2.92% 16.76 17.27 16.42
    Nov 10, 2023 17.02 -0.16 -0.93% 17.18 17.26 16.68
    Nov 9, 2023 17.13 -1.34 -7.26% 18.47 18.47 17.00
    Nov 8, 2023 18.41 -0.68 -3.56% 19.09 19.27 18.20
    Nov 7, 2023 19.57 0.80 4.26% 18.77 19.63 18.28
    Nov 6, 2023 20.50 -0.72 -3.39% 21.22 21.46 20.50
    Nov 3, 2023 21.23 1.63 8.32% 19.60 21.32 19.60
    Nov 2, 2023 19.48 -0.14 -0.71% 19.62 20.09 19.35
    Nov 1, 2023 19.63 1.20 6.51% 18.43 19.70 18.43

    Sage Therapeutics, Inc. Events

    Time (UTC) Country Event
    Thursday, November 30, 2023

    Time (UTC)

    18:30

    Country

    US

    Event

    SAGE Therapeutics Inc at Piper Sandler Healthcare Conference
    SAGE Therapeutics Inc at Piper Sandler Healthcare Conference

    Forecast

    -

    Previous

    -
    Wednesday, February 14, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 SAGE Therapeutics Inc Earnings Release
    Q4 2023 SAGE Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 7.686 6.308 1114.2 6.868 90.273
    Total Operating Expense 554.675 467.217 517.974 714.992 483.511
    Selling/General/Admin. Expenses, Total 227.699 183.498 196.952 345.777 201.404
    Research & Development 326.163 283.166 292.714 368.815 282.107
    Operating Income -546.989 -460.909 596.226 -708.124 -393.238
    Interest Income (Expense), Net Non-Operating 14.19 2.883 9.597 27.804 20.334
    Other, Net 0.015 0.134 0.25 0.082 0.022
    Net Income Before Taxes -532.784 -457.892 606.073 -680.238 -372.882
    Net Income After Taxes -532.784 -457.892 606.073 -680.238 -372.882
    Net Income Before Extra. Items -532.784 -457.892 606.073 -680.238 -372.882
    Net Income -532.784 -457.892 606.073 -680.238 -372.882
    Income Available to Common Excl. Extra. Items -532.784 -457.892 606.073 -680.238 -372.882
    Income Available to Common Incl. Extra. Items -532.784 -457.892 606.073 -680.238 -372.882
    Diluted Net Income -532.784 -457.892 606.073 -680.238 -372.882
    Diluted Weighted Average Shares 59.3061 58.6702 53.0031 50.8338 46.1212
    Diluted EPS Excluding Extraordinary Items -8.98363 -7.8045 11.4347 -13.3816 -8.08483
    Diluted Normalized EPS -8.98363 -7.8045 11.9581 -13.3816 -8.08483
    Total Extraordinary Items
    Revenue 7.686 6.308 1114.2 6.868 90.273
    Cost of Revenue, Total 0.813 0.553 0.565 0.4
    Gross Profit 6.873 5.755 1113.64 6.468
    Unusual Expense (Income) 0 0 27.743
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 2.474 3.294 2.865 1.739 1.501
    Revenue 2.474 3.294 2.865 1.739 1.501
    Cost of Revenue, Total 0.205 0.23 0.143 0.184 0.2
    Gross Profit 2.269 3.064 2.722 1.555 1.301
    Total Operating Expense 172.931 158.764 156.767 143.219 129.908
    Selling/General/Admin. Expenses, Total 75.565 65.708 67.329 61.482 52.411
    Research & Development 97.161 92.826 89.295 81.553 77.297
    Operating Income -170.457 -155.47 -153.902 -141.48 -128.407
    Interest Income (Expense), Net Non-Operating 10.173 8.83 6.793 4.127 2.102
    Other, Net -0.041 -0.188 -0.037 0.03 0.045
    Net Income Before Taxes -160.325 -146.828 -147.146 -137.323 -126.26
    Net Income After Taxes -160.325 -146.828 -147.146 -137.323 -126.26
    Net Income Before Extra. Items -160.325 -146.828 -147.146 -137.323 -126.26
    Net Income -160.325 -146.828 -147.146 -137.323 -126.26
    Income Available to Common Excl. Extra. Items -160.325 -146.828 -147.146 -137.323 -126.26
    Income Available to Common Incl. Extra. Items -160.325 -146.828 -147.146 -137.323 -126.26
    Diluted Net Income -160.325 -146.828 -147.146 -137.323 -126.26
    Diluted Weighted Average Shares 59.7696 59.6741 59.4967 59.4281 59.2663
    Diluted EPS Excluding Extraordinary Items -2.68238 -2.4605 -2.47318 -2.31074 -2.13038
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -2.68238 -2.4605 -2.47318 -2.31074 -2.13038
    Unusual Expense (Income) 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 1336.98 1800.64 2122.37 1035.09 944.695
    Cash and Short Term Investments 1272.49 1742.3 2099.55 1008.39 922.776
    Cash & Equivalents 162.7 294.233 1661.08 126.705 190.943
    Short Term Investments 1109.79 1448.06 438.467 881.688 731.833
    Prepaid Expenses 50.826 39.841 22.821 26.7 21.919
    Total Assets 1356.45 1825.29 2159.25 1084.15 952.705
    Property/Plant/Equipment, Total - Net 13.43 19.125 31.819 42.897 5.643
    Property/Plant/Equipment, Total - Gross 19.525 24.098 38.907 47.396 7.859
    Accumulated Depreciation, Total -6.095 -4.973 -7.088 -4.499 -2.216
    Other Long Term Assets, Total 6.039 5.52 5.057 6.16 2.367
    Total Current Liabilities 99.259 85.193 67.204 112.128 86.03
    Accounts Payable 18.95 10.45 3.691 15.266 34.036
    Accrued Expenses 37.572 26.703 23.931 33.202 19.875
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 42.737 48.04 39.582 63.66 32.119
    Total Liabilities 103.85 96.257 86.912 139.495 89.734
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 4.591 11.064 19.708 27.367 3.704
    Total Equity 1252.6 1729.03 2072.33 944.655 862.971
    Redeemable Preferred Stock 0 0 0 0
    Common Stock 0.006 0.006 0.006 0.005 0.005
    Additional Paid-In Capital 3291.37 3227.47 3109.81 2587.32 1827.02
    Retained Earnings (Accumulated Deficit) -2028.17 -1495.39 -1037.49 -1643.57 -963.329
    Treasury Stock - Common -0.4 -0.4 -0.4 -0.4 -0.211
    Other Equity, Total -10.206 -2.66 0.415 1.295 -0.515
    Total Liabilities & Shareholders’ Equity 1356.45 1825.29 2159.25 1084.15 952.705
    Total Common Shares Outstanding 59.5091 58.937 58.3084 51.8772 46.8883
    Total Receivables, Net 13.66 18.506
    Accounts Receivable - Trade, Net 13.66 18.506
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 933.27 1064.03 1203.44 1336.98 1465.1
    Cash and Short Term Investments 876.052 1002.62 1129.58 1272.49 1393.64
    Cash & Equivalents 148.712 121.416 206.557 162.7 199.826
    Short Term Investments 727.34 881.2 923.028 1109.79 1193.81
    Total Receivables, Net 22.513 15.09 15.002 13.66 18.448
    Accounts Receivable - Trade, Net 22.513 15.09 15.002 13.66 18.448
    Prepaid Expenses 34.705 46.321 58.85 50.826 53.017
    Total Assets 949.663 1082.29 1220.69 1356.45 1486.07
    Property/Plant/Equipment, Total - Net 8.468 10.04 11.725 13.43 14.791
    Property/Plant/Equipment, Total - Gross 19.525
    Accumulated Depreciation, Total -6.095
    Other Long Term Assets, Total 7.925 8.221 5.524 6.039 6.178
    Total Current Liabilities 133.004 96.807 84.692 99.259 99.687
    Accounts Payable 11.136 9.283 12.263 18.95 7.077
    Accrued Expenses 45.985 27.789 18.369 37.572 28.299
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 75.883 59.735 54.06 42.737 64.311
    Total Liabilities 133.004 97.912 87.557 103.85 105.951
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0 1.105 2.865 4.591 6.264
    Total Equity 816.659 984.376 1133.13 1252.6 1380.12
    Redeemable Preferred Stock 0 0 0 0
    Common Stock 0.006 0.006 0.006 0.006 0.006
    Additional Paid-In Capital 3357.74 3325.74 3313.61 3291.37 3276.42
    Retained Earnings (Accumulated Deficit) -2536.95 -2335.32 -2175 -2028.17 -1881.02
    Treasury Stock - Common -0.4 -0.4 -0.4 -0.4 -0.4
    Other Equity, Total -3.735 -5.644 -5.088 -10.206 -14.883
    Total Liabilities & Shareholders’ Equity 949.663 1082.29 1220.69 1356.45 1486.07
    Total Common Shares Outstanding 59.8839 59.796 59.762 59.5091 59.4937
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -532.784 -457.892 606.073 -680.238 -372.882
    Cash From Operating Activities -460.036 -378.182 664.28 -528.706 -260.671
    Cash From Operating Activities 1.122 4.182 2.63 2.283 1.143
    Non-Cash Items 65.955 94.034 95.306 142.591 91.856
    Changes in Working Capital 5.671 -18.506 -39.729 6.658 19.212
    Cash From Investing Activities 325.433 -1002.45 442.684 -143.156 -512.461
    Capital Expenditures -0.937 -0.372 -0.345 -5.751 -2.86
    Other Investing Cash Flow Items, Total 326.37 -1002.08 443.029 -137.405 -509.601
    Cash From Financing Activities 3.07 13.334 426.762 607.624 659.358
    Financing Cash Flow Items -0.043 -1.385 -2.503 -1.244
    Issuance (Retirement) of Stock, Net 3.113 14.719 426.762 610.127 660.602
    Net Change in Cash -131.533 -1367.3 1533.73 -64.238 -113.774
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -146.828 -532.784 -385.638 -248.315 -122.055
    Cash From Operating Activities -153.682 -460.036 -333.104 -214.239 -107.8
    Cash From Operating Activities 0.323 1.122 0.832 0.554 0.275
    Non-Cash Items 16.83 65.955 52.076 37.849 20.897
    Changes in Working Capital -24.007 5.671 -0.374 -4.327 -6.917
    Cash From Investing Activities 194.867 325.433 235.656 124.704 -9.558
    Other Investing Cash Flow Items, Total 195.092 326.37 236.311 124.995 -9.389
    Cash From Financing Activities 2.672 3.07 3.041 1.812 1.799
    Issuance (Retirement) of Stock, Net 3.301 3.113 3.08 1.836 1.799
    Net Change in Cash 43.857 -131.533 -94.407 -87.723 -115.559
    Capital Expenditures -0.225 -0.937 -0.655 -0.291 -0.169
    Financing Cash Flow Items -0.629 -0.043 -0.039 -0.024
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Fidelity Management & Research Company LLC Investment Advisor 14.6778 8789617 1706204 2023-06-30 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 10.6266 6363630 649207 2023-06-30 LOW
    Biogen Inc Corporation 10.4226 6241473 0 2023-03-31 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.3815 5019202 53550 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.9624 3570538 -11550 2023-06-30 LOW
    Bellevue Asset Management AG Investment Advisor 5.2007 3114375 24375 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.8393 2299140 -435233 2023-06-30 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.866 1716268 61568 2023-06-30 LOW
    JP Morgan Asset Management Investment Advisor 1.857 1112064 291861 2023-06-30 LOW
    Boxer Capital, L.L.C. Hedge Fund 1.8269 1094000 0 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7827 1067545 27300 2023-06-30 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 1.7505 1048295 -829697 2023-06-30 LOW
    DWS Investment GmbH Investment Advisor/Hedge Fund 1.6699 1000000 300000 2023-06-30 LOW
    Palo Alto Investors LP Hedge Fund 1.4353 859517 0 2023-06-30 LOW
    Lord, Abbett & Co. LLC Investment Advisor 1.382 827577 637244 2023-06-30 MED
    Marshall Wace LLP Investment Advisor/Hedge Fund 1.3335 798548 -613381 2023-06-30 HIGH
    Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 1.0796 646495 -228289 2023-06-30 LOW
    Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 1.0001 598918 592380 2023-06-30 LOW
    Manulife Investment Management (North America) Limited Investment Advisor 0.9918 593938 -30733 2023-06-30 LOW
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.864 517402 26317 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Sage Therapeutic Company profile

    About SAGE Therapeutics Inc

    SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).

    Equity composition

    Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.

    Industry: Bio Therapeutic Drugs

    215 1st St
    CAMBRIDGE
    MASSACHUSETTS 02142
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023

    People also watch

    BTC/USD

    37,680.65 Price
    -0.230% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    XRP/USD

    0.61 Price
    -1.020% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Gold

    2,038.54 Price
    -0.310% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    US100

    15,875.40 Price
    -0.730% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading